Stalled growth, halved profit; restructuring play with R&D upside

₹155.1 stated on call; delivered result ₹151.1 Cr — overstated by 2.6%

₹8.9 Cr delivered matches; but -42.7% YoY is severe collapse

₹24.1Cr EBITDA ÷ ₹155.1Cr = 15.6% ✓; but down 32.4% YoY dollars — margin held, volume fell

Q1 revenue -6.5% YoY base; acid chloride ramp possible but macro headwinds remain; aspiration not anchored

Formula held in Q1; but management acknowledges margin-per-kilo risk if competition escalates; rupee depreciation passed through

Prior: ₹200Cr capex (FY21–26) was reactive/maintenance. Now: ₹250Cr Odisha greenfield (FY27–32) + multi-purpose pilot plant (design done, build starting) ahead of customer validation. Board shift to 'aggressive' (new board 1.5–2yr). Signals willingness to front-load R&D, not just follow.

Prior guidance: 10–12% CAGR (multiple calls). Now: vague '15–20% growth this year' (₹151Cr base → ₹174–181Cr) + 'double in 5–6 years'. Reality Q1: -6.5% YoY. Target is aspirational hedging, not commitment.

Feb 2025 call promised ₹150–200Cr annual revenue from 3–4 new products. Now (Aug 2026): 2 products ₹50Cr each by FY28, others 'later'. Battery electrolyte product paused (customer tech changed). One polymer held at pilot stage.

₹300Cr (45% of market cap) earning ₹5–7Cr dividend (1.7–2.3% yield), flat/declining. Non-liquid under shareholder agreement. Dragging ROE; management frustrated but stuck. Prior: no active discussion. Now: admitting impasse.

Chemical industry has had ups & downs; uncertainties happen. New board (1.5–2yr old) is now 'aggressive' on growth. This year expecting 15–20% growth; new acid chlorides ₹4Cr → ₹15Cr. Doubling revenue in 5–6 years.

Each plant product-specific with separate streams, not batch-switchable like pharma. Capacity mix constraint: if customer A wants 1,200 units/yr at stream 1, customer B wants 5,000 at stream 2, etc., total permission-level exceeds utilization by 20–30%. So even at 100% permission, only 70–75% capacity utilization. New facilities (Odisha) needed for new product families.

Capex was mostly maintenance & replacement (old unsafe plants dismantled, thionyl chloride backward integration). Not true growth capex. Those didn't add revenue. Going forward, capex will be tied to specific products/groups; will disclose objectives via stock exchange.

2 products near commercialization: one ₹50Cr annual revenue (pilot lot 5MT to customer Q4 FY27), second ₹50Cr (commercialization end FY27, revenue in FY28). Others under development, markets big but customers not yet identified. AI being used to accelerate R&D.

Chinese focus low-end (bags, low-tier auto); DuPont/Arclin in mission-critical (aerospace, high-temp). No direct competition. Arclin may face cost pressure but no evidence yet of pricing pressure on us. They're optimizing utilization; higher volumes offset lower per-kilo margin.

Respect sentiment; will improve. May not disclose product-specific EBITDA due to confidentiality & competitive risk. Will try to provide broader detail.

Discussions ongoing but not resolved. Shareholder agreement requires Silox agreement to accept new buyer. They're investing heavily (Dahej, Odisha plots), unlikely to part with cash soon. No near-term exit expected.

Chemical industry volatile; no company consistent 15% EBITDA 8–10yr (even largest swing 20%→9%→7%→11%). Transpek at 15% is stable. Target 15–20% forward. Can't set hurdle rate; raw material swings mean 20% margin product may drop to 11% in 3mo; can't exit, must maintain share & wait.

4–5 years payback period.

No. Pilot plant at Ekalbara, ready Feb 2027. Odisha still under board approval and government feasibility. Pilot plant will help scale new products to tonnage before commercial investment.

Acid chloride ramp ₹4→₹15Cr main driver (₹11Cr delta); other products incremental. Macro headwinds acknowledged (West Asia, competition); aspiration not contractual.

Current 15.6%; target band acknowledges raw material volatility. No hedging disclosed; pass-through to customers varies (Arclin formula-based, others negotiated). Margin-per-kilo may compress but volume offset assumed.

Board approval expected Sep 2026. Government approvals (EC, permissions) 3–4 months. Construction 1–1.5yr. Commercial production FY29-30 earliest. Phased spend; no annual breakout given.

Arclin (ex-DuPont) likely ₹70–80Cr+ (50%+ of revenue). Contract renewal Q4 FY27/Q1 FY28. Management confident ('no reason not to renew') but Chinese/Korean competition acknowledged. Non-renewal would devastate revenue & profitability.

Feb 2025 promised ₹150–200Cr from 3–4 new products. Now 2 products ₹50Cr each by FY28, others 'later.' Battery electrolyte product paused (customer tech change). 3 polymers at pilot stage (6–7mo pilot plant build, then scale trials). No customer lock-in for most. Timeline creep evident.

₹250Cr Odisha capex (FY27–32) targeting 4–5yr payback. Prior ₹200Cr capex (FY21–26) mostly maintenance (plant replacement, thionyl chloride), not growth; EBITDA flat/down despite spend. New capex phased but unproven track record of execution & returns.

₹300Cr investment (45% of market cap) in Silox, earning ₹5–7Cr dividend (1.7–2.3% yield), flat/declining. Illiquid under shareholder agreement (Prayon can refuse new buyer). Traps capital; impairs ROE; no exit plan. Management frustrated but constrained.

Raw material (e.g., thionyl chloride cost) swings ₹2,600→₹4,000/ton in 10 days. Arclin on cost-plus, others negotiated — pass-through lags. Currency: rupee depreciation (23% vs dollar 6yr) helps export margins but unpredictable. West Asia (Houthis, Red Sea) cited as logistics risk.